Skip to content
Triangle logo TriangleGet started
← Non-Small Cell Lung Cancer

HEALTH PROFESSIONAL · SOURCE READING

KRAS G12C inhibitors (for patients with KRAS G12C variants)

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)

Activating KRAS variants are found in 25% to 30% of nonsquamous NSCLC, resulting in activation of downstream oncogenic pathways and uncontrolled growth. The G12C single nucleotide variant, with glycine substituted by cysteine at codon 12, is the most frequent variant in NSCLC, occurring in approximately 13% of lung adenocarcinomas.[57]

Source links and citations

Continue within this section

Adagrasib →Sotorasib →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice